<DOC>
	<DOCNO>NCT02888990</DOCNO>
	<brief_summary>1 . The use imatinib combination association chemotherapy consider gold standard treatment Ph+ ALL . The complete remission ( CR ) rate 90 % versus 20 % 40 % chemotherapy alone . The combination imatinib , vincristine dexamethasone well tolerated regimen age patient also associate high CR rate 80 % 90 % patient age 55 year . 2 . However , despite high CR rate , progression free survival rate 12 month patient treated combination imatinib chemotherapy 30 % 50 % . Relapses remain frequent patient intensify allogenic haematopoietic stem cell transplantation long term remission . This strategy fully applicable patient age 55 year . 3 . Relapses imatinib therapy patient Ph+ ALL associate BCR-ABL tyrosine kinase domain mutation 80 % case , predominantly p-loop . The exact incidence T315I mutation controversial estimate near 50 % . Conversely , detection T315I F317 mutation patient strong predictor relapse . 4 . Dasatinib potent SCR BCR-ABL tyrosine kinase inhibitor preserve vitro activity BCR-ABL mutate cell line , except T315I F317 mutation . This also case vivo , patient harbour BCR-ABL TK domain mutation remain sensitive dasatinib . The CHR rate Ph+ ALL resistant imatinib 33 % median progression-free survival 3.7 month . Progression free survival ( PFS ) rate 12 month 22 % . The goal trial evaluate efficacy tolerance combination dasatinib chemotherapy front-line set induction consolidation therapy Ph+ ALL patient age 55 year . A European consensus reach adopt common chemotherapeutic schedule patient age 55 year . This schedule use trial addition dasatinib concomitant therapy induction alternate chemotherapy consolidation maintenance . A CR rate 90 % progression free survival 60 % 12 month expect . The patient prospectively monitor minimal residual disease mutation .</brief_summary>
	<brief_title>Dasatinib Low Intensity Chemotherapy Ph+ Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Male female patient â‰¥ 55 year 2 . Philadelphia chromosome BCRABL positive acute lymphoblastic leukaemia 3 . Not previously treat except corticosteroid single dose vincristine ( three dos cyclophosphamide accept recommend ) 4 . With without documented CNS involvement 5 . Signed write inform consent 6 . Molecular evaluation BCRABL do 1 . Patients ECOG status &gt; 2 2 . Patient previously treat Tyrosine Kinase Inhibitors 3 . Patients QTc &gt; 470 m 4 . Heart insufficiency NYHA grade III/IV , LEVF &lt; 50 % RF &lt; 30 % , myocardial infarction within past 6 month prior study 5 . Active secondary malignancy 6 . Patients active bacterial , viral fungal infection 7 . Known infection HIV , Hepatitis B ( except post vaccinal profile ) C 8 . Treatment , investigational agent participate another trial within 30 day prior enter study 9 . Inadequate hepatic function define ASAT ALAT &gt; 2,5 time institutional upper limit normal total bilirubin &gt; 2 fold institutional upper limit unless consider due organ involvement leukemia 10 . Concurrent severe disease exclude administration therapy</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>